22 results about "Naproxenum" patented technology

The invention particularly relates to a method for determining a reaction rate constant of tetravalent iron and organic pollutants by using a chemiluminescence method, and belongs to the technical field of water quality detection. According to the method, on the basis of a chemiluminescence reaction between Fe (IV) and naproxen (NAP), a target organic pollutant (TrOC) is introduced, the quenching effect of the target organic pollutant on a chemiluminescence signal is measured, and a competitive kinetic model between the chemiluminescence quenching capacity (CLQC) and a secondary reaction rate constant (kFe (IV), TrOC) of Fe (IV) on the target pollutant is constructed. According to the method, the concentration of Fe (IV) does not need to be monitored in real time, and the reaction activity between Fe (IV) and various pollutants can be directly and rapidly measured only by comparing the intensity change of the chemiluminescence signals when the target pollutants exist and do not exist.

The present application relates to a kind of carbonized iron and nitrogen coordination iron co-doped nitrogen and graphene carbon material and preparation method and application, with six hydrated ferric chloride as iron source, with chitin as nitrogen, carbon source. By simple one-step method, after mixing, calcination, grinding way, carbonized iron and nitrogen coordination iron co-doped nitrogen and graphene carbon material is synthesized.The material prepared by the present application presents two-dimensional layered structure, after adding potassium hydrogen peroxodisulfate oxidant, the material can completely remove the active pharmaceutical ingredient naphthyl in water in a short time.Naproxen.The synthesis method proposed in the present application is simple and easy to operate, and the material performance is excellent, which can provide a new design idea for nitrogen coordination iron nanomaterial supported by carbon material, and be applied to the remediation of contaminated water.

A composition comprises an alkali metal salt of a first pharmaceutical ingredient; and a second pharmaceutical ingredient, wherein the second pharmaceutical ingredient is chemically incompatible with the first pharmaceutical ingredient, and the composition is an aqueous solution. The first active pharmaceutical ingredient can comprise ibuprofen or naproxen. The second pharmaceutical ingredient can comprise acetaminophen.

The invention discloses a sulfur-doped bi-metal cobalt cerium oxide Fenton-like catalyst and a preparation method and application thereof.The sulfur-doped bi-metal cobalt cerium oxide Fenton-like catalyst is a sulfur-doped cobalt cerium composite oxide, and in the sulfur-doped bi-metal cobalt cerium oxide Fenton-like catalyst, the Co element content is 20-24 wt%, the Ce element content is 50-56 wt%, the O element content is 20-22 wt%, and the balance is a carrier. The content of the S element is 1-4 wt%. According to the sulfur-doped bimetallic cobalt cerium oxide Fenton-like catalyst disclosed by the invention, peroxyacetic acid is activated to generate organic oxygen free radicals, and 90.5% of moxifloxacin can be degraded within 15 minutes; and the composite material has a good degradation effect on pollutants of polycyclic aromatic compounds such as ofloxacin, gatifloxacin, norfloxacin, tetracycline, o-nitrophenol, naproxen and the like.

This invention relates to the fields of environmental and chemical technology, specifically to a nitrogen-modified activated carbon adsorbent material, its preparation method, and its applications. The invention employs an ammonium chloride solution impregnation method combined with high-temperature activation under a nitrogen inert atmosphere to modify the surface of pretreated granular activated carbon, increasing the content of basic groups on the activated carbon surface, thus preparing a nitrogen-modified activated carbon adsorbent material. Experimental results show that the prepared nitrogen-modified activated carbon exhibits high adsorption efficiency for carboxylic acid drug pollutants such as naproxen, ibuprofen, and diclofenac. The preparation conditions of this invention are mild, the operation steps are simple, the required reagents are inexpensive, and the safety is relatively high, making it suitable for the treatment of drinking water, sewage, and medical wastewater.

An object of the present application is to provide a pharmaceutical composition which improves the anti-inflammatory effect of loxoprofen. According to the present application, there is provided a pharmaceutical composition comprising: at least one selected from the group consisting of loxoprofen, salts thereof, and hydrates thereof, and at least one selected from the group consisting of diclofenac, naproxen, salts thereof, and hydrates thereof.

This invention discloses a chiral covalent organic framework composite membrane prepared by in-situ growth and its applications. This invention uses [NALC] as a reference. X -TAPB-DVA COF S As a functionalized material, a chiral covalent organic framework composite membrane was prepared by a secondary in-situ growth method using terephthalaldehyde (PAD) as the linker and 1,3,5-tris(4-aminophenyl)benzene (TAPB) as the nucleation site. This chiral covalent organic framework composite membrane can resolve enantiomers of mandelic acid, warfarin, naproxen, and ibuprofen, exhibiting a wide resolution range and stable resolution performance.

This invention discloses a method for preparing a cyclodextrin-ammonium acetate-naproxen ternary inclusion complex, comprising the following steps: mixing β-cyclodextrin, naproxen, and ammonium acetate in a molar ratio of 0.8-1.3:0.9-1.1:0.8-2.5 with a solvent; stirring the resulting mixture at 35-45°C for 0.5-2 hours; and then removing the solvent by evaporation, standing, and freeze-drying to obtain the ternary complex. This invention prepares a ternary inclusion complex using β-cyclodextrin, naproxen, and ammonium acetate, which significantly improves drug stability and water solubility, thus helping to enhance the bioavailability of naproxen and expand its application areas.

The invention discloses a method for detecting an impurity I in naproxen. A naproxen raw material medicine and 1, 2, 4, 5-tetracyanobenzene (TCBB) are fully ground and evenly mixed, then a fluorescence signal is detected under the 365 nm ultraviolet irradiation condition, if green fluorescence is generated, it is indicated that the raw material medicine contains the impurity I, and otherwise, it is indicated that the raw material medicine does not contain the impurity I. The fluorescent probe TCNB and the naproxen impurity I can generate specific intermolecular charge transfer interaction, so that a fluorescent signal is generated, and the visual impurity inspection of the naproxen impurity I is realized. According to the method, the probe and the naproxen impurity I can interact with each other through a grinding method which is simple, convenient and easy to operate, so that bright green fluorescence is generated, 0.1% of limited impurities can still be detected, and meanwhile, the probe cannot interact with naproxen, so that the detection of the impurity I is not interfered. Therefore, the impurity detection method provided by the invention has low detection limit, good specificity and anti-interference capability, can effectively analyze the trace impurity I in naproxen without pretreatment, and has a wide application prospect.

Here described is a pharmaceutical composition comprising a fill material comprising: a salt of one or more pharmaceutically active agents; and a lipid-based water-soluble surfactant. The fill material may further comprise a lipid-based oil and wetting agent. The lipid-based oil may be medium-chain triglycerides and the wetting agent may be lecithin.

The invention belongs to the field of RS-naproxen chiral resolution, and relates to a metal organic framework chiral separation membrane as well as a preparation method and application thereof. The preparation method of the metal organic framework chiral separation membrane comprises the steps that a chiral selection solution is evenly laid on a PVDF base membrane and then subjected to vacuum suction filtration, and the chiral selection solution is an aqueous solution containing hydroxypropyl-beta-cyclodextrin, sulfobutyl-beta-cyclodextrin, N-ethylaniline, diphenyl sulfoxide and alkali metal hydroxide; and heating the obtained membrane in a methanol steam environment, and washing with water to obtain the metal organic framework chiral separation membrane. The metal organic framework chiral separation membrane obtained by the method has good separation performance and stability when being used for chiral resolution of RS-naproxen.

The application discloses a kind of advanced oxidation device and method for degrading new pollutants in water, the device includes reaction pool, ozone generator, sulfite storage tank, ozone generator is used to add ozone to reaction pool, sulfite storage tank is used to add sulfite to reaction pool;Reaction pool is equipped with water inlet and water outlet. When using, inject the water sample to be treated into reaction pool, start ozone generator, sulfite storage tank to carry out the addition of ozone and sulfite;The molar ratio of ozone and sulfite addition in reaction pool is 5:1~1:1, the molar ratio of new pollutant concentration in the water sample to be treated and ozone addition amount is: 1:10~1:100.The advanced oxidation system of ozone activated sulfite constructed by the application has high yield of sulfate radical and hydroxyl radical, and can rapidly degrade new pollutants within 5 minutes, and the degradation efficiency of new pollutants such as naproxen, sulfamethoxazole, carbamazepine, atrazine and chloramphenicol in water reaches more than 80%.

This invention relates to a method for resolving (+)-isomenthyl alcohol, comprising the following steps: under nitrogen protection, racemic isomenthyl alcohol, S-naproxen, and a solvent are added to a reaction vessel, stirred and heated to reflux, and reacted at a constant temperature to obtain a reaction solution containing (±)-isomenthyl alcohol-S-naproxen ester. The solution is then post-treated to obtain crude racemic isomenthyl alcohol-naproxen ester. The crude product is dissolved in methanol and crystallized by cooling to obtain a primary crystallization product. The primary crystallization product is subjected to a secondary crystallization by repeating the above crystallization steps, and optically pure (+)-isomenthyl alcohol-S-naproxen ester is collected. The (+)-isomenthyl alcohol-S-naproxen ester is dissolved in methanol, and an aqueous hydroxide solution is added. The mixture is stirred and hydrolyzed, and after removing the methanol, it is extracted with an organic solvent. The final product is then post-treated to obtain pure (+)-isomenthyl alcohol. Compared with existing technologies, this invention has advantages such as simple operation, mild reaction conditions, high product purity, and easy recovery of the resolving agent, effectively solving the problems of impurity encapsulation and easy configuration inversion in traditional resolving methods.

An improved immediate release solid dosage form of naproxen with a certain particle size distribution for the intragranular portion, and a certain particle size distribution for the carbonate portion that allows naproxen to remain in solution and achieves fast dissolution and fast absorption of naproxen. The invention provides a naproxen dosage form that when administered to a human in a fasted state provides an average blood plasma naproxen concentration of at least 15-20 μg / ml in 10 minutes or less. The invention also provides a naproxen dosage form that when administered to a human in a fed state provides an average blood plasma naproxen concentration of at least 15-20 μg / ml in 50 minutes or less.

The present invention relates to a pharmaceutical composition in the form of bilayer tablet comprising a) first layer comprising granules or powder containing Naproxen and at least one pharmaceutically acceptable excipient, and b) second layer comprising dry granulated granules containing Esomeprazole and its pharmaceutically acceptable salt and at least one pharmaceutically acceptable excipient. The invention further relates to a process for the preparation of said pharmaceutical composition.

The application relates to a drug controlled release system with a chiral drug selective loading function, a preparation method and application thereof, and belongs to the technical field of biological medicines. The drug controlled release system with the chiral drug selective loading function is prepared into a supermolecular hydrogel selective loading system after a gel factor is self-assembled into a supermolecular hydrogel, and chiral drugs with the same optical rotation as the supermolecular hydrogel are loaded into a three-dimensional network structure of the supermolecular hydrogel. The drug controlled release system with the chiral drug selective loading function prepared by the application can realize selective loading of different configurations of naproxen, and can realize controlled release of S-naproxen under alkaline conditions. The chiral selective controlled release system is simple in preparation, high in feasibility, and can be widely applied to the field of biological medicines.

The invention discloses a 3-trifluoroalkyl quinoxaline-2 (1H)-ketone compound and a preparation method thereof, and relates to the technical field of organic synthesis. The invention provides a method for preparing a 3-trifluoroalkyl quinoxaline-2 (1H)-ketone compound by taking bromotrifluoromethane as a trifluoromethyl reagent through three components of bromotrifluoromethane, 1-methylquinoxaline-2 (1H)-ketone and olefin by a one-pot method in one step under the action of visible light induction and amidine organic alkali. According to the preparation method provided by the invention, the derivatives of ibuprofen and naproxen are synthesized for the first time. The preparation method disclosed by the invention has the characteristics of cheap and easily available raw materials, no need of adding a noble metal photosensitizer, simplicity in operation, mild reaction conditions, greenness, safety, excellent reaction yield and the like.

The application discloses a method for degrading naproxen in water by using a divalent manganese / percarbonate / tetraacetylethylenediamine system and relates to a method for degrading naproxen in water by using a high-level oxidation technology. The method comprises the following steps: adding percarbonate and tetraacetylethylenediamine into water to be treated containing naproxen, adjusting the pH value of the water to be treated to 5-10, adding divalent manganese for treatment, and stirring and reacting for 10-60 minutes at a water temperature of 5-35 DEG C. The method has the advantages of fast generation speed of active species, high removal efficiency of organic pollutants, high utilization rate of oxidants, no need to increase other treatment equipment, low one-time investment cost, low operation cost, simple operation, wide application range, green environmental protection and the like, and has a wide application prospect in the treatment of organic wastewater, such as medical wastewater and aquaculture wastewater, containing naproxen.

The invention belongs to the technical field of medicinal gel, and particularly relates to bifunctional naproxen lidocaine ionic liquid gel as well as a preparation method and application thereof. Naproxen, sodium hydroxide and lidocaine hydrochloride are used as raw materials, and the naproxen and lidocaine ionic liquid is synthesized by adopting an ethanol system two-step method. The naproxen and lidocaine ionic liquid gel is prepared through blank gel matrix drug loading. Under the condition of the same drug loading capacity, the prepared naproxen lidocaine ionic liquid gel is better in transdermal effect and higher in transdermal rate. The auxiliary ionic liquid is added into the naproxen lidocaine ionic liquid gel, so that the penetration enhancing performance is improved, meanwhile, the green and low-toxicity choline lactate ionic liquid is synthesized, the toxic and side effects and the irritation can be remarkably reduced, and the naproxen lidocaine ionic liquid gel has the clinical application potential.

The invention belongs to the field of chiral resolution of RS-naproxen, and relates to a chiral resolution method of RS-naproxen, which comprises the following steps: separating an RS-naproxen enantiomer solution to be separated by using a carbon-based chiral separation membrane; the chiral separation membrane is a separation membrane prepared by taking a PVDF (Polyvinylidene Fluoride) base membrane as a bottom membrane and taking composite beta-cyclodextrin and multi-element acyl chloride as two-phase monomers to carry out interfacial polymerization reaction; the compound beta-cyclodextrin contains hydroxypropyl-beta-cyclodextrin and sulfobutyl-beta-cyclodextrin, and the compound beta-cyclodextrin contains hydroxypropyl-beta-cyclodextrin and sulfobutyl-beta-cyclodextrin; the multi-element acyl chloride contains trimesoyl chloride and 5-isocyanate isophthaloyl chloride, and the method has good separation performance and stability.